Search

Your search keyword '"Cella C"' showing total 144 results
Start Over Author "Cella C"
144 results on '"Cella C"'

1. Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study

Author

Gervaso, L, Laffi, A, Gaeta, A, Gandini, S, Boldrini, L, Meneses-Medina, M, Rubino, M, Benini, L, Borghesani, M, Algeri, L, Curigliano, G, Spada, F, Cella, C, Fazio, N, Gervaso L., Laffi A., Gaeta A., Gandini S., Boldrini L., Meneses-Medina M. I., Rubino M., Benini L., Borghesani M., Algeri L., Curigliano G., Spada F., Cella C. A., Fazio N., Gervaso, L, Laffi, A, Gaeta, A, Gandini, S, Boldrini, L, Meneses-Medina, M, Rubino, M, Benini, L, Borghesani, M, Algeri, L, Curigliano, G, Spada, F, Cella, C, Fazio, N, Gervaso L., Laffi A., Gaeta A., Gandini S., Boldrini L., Meneses-Medina M. I., Rubino M., Benini L., Borghesani M., Algeri L., Curigliano G., Spada F., Cella C. A., and Fazio N.

Published
2024

2. Machine listening intelligence

Author

Cella, C. E.

Subjects
Computer Science - Sound, Computer Science - Learning, 68Txx, C.1.3, H.5.1
Abstract

This manifesto paper will introduce machine listening intelligence, an integrated research framework for acoustic and musical signals modelling, based on signal processing, deep learning and computational musicology., Comment: Proceedings of the First International Conference on Deep Learning and Music, Anchorage, US, May, 2017 (arXiv:1706.08675v1 [cs.NE])

Published
2017

3. Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome : a retrospective experience from two European referral centers

Author

Algeri, L., Falkman, Lovisa, Spada, F., Frassoni, S., Bagnardi, V., Boselli, S., Cardinale, D., Zanobini, M., Crona, Joakim, Benini, L., Tamayo, D., Mazzon, C., Gervaso, L., Cella, C. A., Zampino, M. G., Ciardiello, D., Russo, A., Badalamenti, G., Welin, Staffan, Fazio, N., Algeri, L., Falkman, Lovisa, Spada, F., Frassoni, S., Bagnardi, V., Boselli, S., Cardinale, D., Zanobini, M., Crona, Joakim, Benini, L., Tamayo, D., Mazzon, C., Gervaso, L., Cella, C. A., Zampino, M. G., Ciardiello, D., Russo, A., Badalamenti, G., Welin, Staffan, and Fazio, N.

Abstract

Background: Up to 50% of patients with advanced small-intestinal neuroendocrine tumors (SI-NETs) and carcinoid syndrome (CS) develop carcinoid heart disease (CHD). However, the true frequency and prognostic markers for CHD in CS are lacking. We described the real-world management of patients in two NET referral centers in this clinical context and relationships between clinical features, including CHD and overall survival (OS). Patients and methods: This is a retrospective analysis of patients with stage IV SI-NET and CS, treated at the European Institute of Oncology in Milan and Uppsala University in Sweden between 2015 and 2021. CHD was defined as at least one moderate right-sided heart valve defect. Median OS and cumulative incidence of CHD were estimated from the diagnosis of metastatic disease, and the association between clinical parameters with both OS and occurrence of CHD was evaluated. Results: We included 165 patients, with 97% having low-intermediate-grade SI-NETs and 86% having synchronous liver metastases. Ninety-eight patients (59%) became refractory to full label dose of somatostatin analogues and 25% developed a CHD. At CHD diagnosis, baseline urine 5-hydroxyindoleacetic acid (24-h u5-HIAA) value and plasma Nterminal pro-brain natriuretic peptide (NT-proBNP) value were known in 76% of patients. Moderate-to-severe tricuspid insufficiency was the most common alteration of CHD. Prognosis was significantly impaired by CHD (multivariable hazard ratio for OS = 2.85, P < 0.001). The median OS from the CHD diagnosis was 4.5 years [95% confidence interval (CI) 2.1-7.2 years], and the 5-year survival rate was 34% (95% CI 13% to 57%). Conclusions: In our study population of SI-NET patients with CS, more than half had a refractory carcinoid syndrome (RCS) and one-quarter developed a CHD, with a negative impact on OS. Therefore, it is recommended to screen and monitor patients with CS for CHD, ideally with a combination of u5-HIAA, NT-proBNP values, and echoc

Published
2024
Full Text
View/download PDF

4. Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy

Author

Gervaso, L, Bottiglieri, L, Meneses-Medina, M, Pellicori, S, Biffi, R, Fumagalli Romario, U, De Pascale, S, Sala, I, Bagnardi, V, Barberis, M, Cella, C, Fazio, N, Gervaso L., Bottiglieri L., Meneses-Medina M. I., Pellicori S., Biffi R., Fumagalli Romario U., De Pascale S., Sala I., Bagnardi V., Barberis M., Cella C. A., Fazio N., Gervaso, L, Bottiglieri, L, Meneses-Medina, M, Pellicori, S, Biffi, R, Fumagalli Romario, U, De Pascale, S, Sala, I, Bagnardi, V, Barberis, M, Cella, C, Fazio, N, Gervaso L., Bottiglieri L., Meneses-Medina M. I., Pellicori S., Biffi R., Fumagalli Romario U., De Pascale S., Sala I., Bagnardi V., Barberis M., Cella C. A., and Fazio N.

Abstract

Purpose: Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced gastric cancer (LAGC). Several biomarkers, including HER2 and MMR/MSI are crucial for treatment decisions in the advanced stage but, currently, no biomarkers can guide the choice of NAC in clinical practice. Our aim was to evaluate the role of MSI and HER2 status on clinical outcomes. Methods: We retrospectively collected LAGC patients treated with NAC and surgery +/- adjuvant chemotherapy from 2006 to 2018. HER2 and MSI were assessed on endoscopic and surgical samples. Pathologic complete response (pCR) rate, overall survival (OS), and event‐free survival (EFS) were estimated and evaluated for association with downstaging and MSI. Results: We included 76 patients, 8% were classified as MSI-H, entirely consistent between endoscopic and surgical samples. Six percent of patients were HER2 positive on endoscopic and 4% on surgical samples. Tumor downstaging was observed in 52.5% of cases, with three pCR (5.1%), none in MSI-H cancers. According to MSI status, event-free survival (EFS) and overall survival (OS) were higher for MSI-H patients to MSS [EFS not reached vs 30.0 months, p = 0.08; OS not reached vs 39.6 months, p = 0.10]. Conclusion: Our work confirms the positive prognostic effect of MSI-H in the curative setting of LAGC, not correlated with pathologic tumor downstaging. Prospective ad-hoc trial and tumor molecular profiling are eagerly needed.

Published
2023

5. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients with Cancer

Author

Cella, C, Knoedler, M, Hall, M, Arcopinto, M, Bagnardi, V, Gervaso, L, Pellicori, S, Spada, F, Zampino, M, Ravenda, P, Frassoni, S, Passaro, A, Milano, M, Laffi, A, Fazio, N, Lordick, F, Cella C. A., Knoedler M., Hall M., Arcopinto M., Bagnardi V., Gervaso L., Pellicori S., Spada F., Zampino M. G., Ravenda P. S., Frassoni S., Passaro A., Milano M., Laffi A., Fazio N., Lordick F., Cella, C, Knoedler, M, Hall, M, Arcopinto, M, Bagnardi, V, Gervaso, L, Pellicori, S, Spada, F, Zampino, M, Ravenda, P, Frassoni, S, Passaro, A, Milano, M, Laffi, A, Fazio, N, Lordick, F, Cella C. A., Knoedler M., Hall M., Arcopinto M., Bagnardi V., Gervaso L., Pellicori S., Spada F., Zampino M. G., Ravenda P. S., Frassoni S., Passaro A., Milano M., Laffi A., Fazio N., and Lordick F.

Abstract

Importance: The assessment of the risk of venous thromboembolism (VTE) among outpatients with cancer represents an unsolved topic. Current international guidelines recommend primary prophylaxis for patients at intermediate to high risk of VTE, indicated by a Khorana score of 2 or more. A previous prospective study developed the ONKOTEV score, a 4-variable risk assessment model (RAM) consisting of a Khorana score of more than 2, metastatic disease, vascular or lymphatic compression, and previous VTE event. Objective: To validate the ONKOTEV score as a novel RAM to assess the risk of VTE among outpatients with cancer. Design, Setting, and Participants: ONKOTEV-2 is a noninterventional prognostic study conducted in 3 European centers located in Italy, Germany, and the United Kingdom among a prospective cohort of 425 ambulatory patients with a histologically confirmed diagnosis of a solid tumor who were receiving active treatments. The total study duration was 52 months, with an accrual period of 28 months (from May 1, 2015, to September 30, 2017) and an overall follow up-period of 24 months (data were censored September 30, 2019). Statistical analysis was performed in October 2019. Exposures: The ONKOTEV score was calculated for each patient at baseline by collecting clinical, laboratory, and imaging data from tests performed for routine practice. Each patient was then observed to detect any thromboembolic event throughout the study period. Main Outcomes and Measures: The primary outcome of the study was the incidence of VTE, including deep vein thrombosis and pulmonary embolism. Results: A total of 425 patients (242 women [56.9%]; median age, 61 years [range, 20-92 years]) were included in the validation cohort of the study. The cumulative incidences for the risk of developing VTE at 6 months were 2.6% (95% CI, 0.7%-6.9%), 9.1% (95% CI, 5.8%-13.2%), 32.3% (95% CI, 21.0%-44.1%), and 19.3% (95% CI, 2.5%-48.0%), respectively, among 425 patients with an ONKOTEV score of 0

Published
2023

6. Soil tillage to reduce surface metal contamination - model development and simulations of zinc and copper concentration profiles in a pig slurry-amended soil

Author

Mallmann, FJK, Rheinheimer, DDS, Ceretta, CA, Cella, C, Minella, JPG, Guma, RL, Filipović, V, van Oort, F, and Šimůnek, J

Subjects
Hydrus-1D, Trace metals, Organic waste, Solute movement, Groundwater pollution, Surface accumulation, Agronomy & Agriculture, Environmental Sciences, Agricultural and Veterinary Sciences, Studies in Human Society
Abstract

Long-term applications of organic amendments, such as pig slurry (PS), may represent environmental risk of soil and water pollution by trace metals (TM). Our objective was to examine different soil and manure management scenarios that enhance the long-term agricultural use of soils under repetitive PS applications while avoiding environmental risk. Firstly, we developed a new module for simulating the impacts of soil tillage frequencies in Hydrus-1D. Secondly, we used a previously validated modeling approach to predict the surface accumulation and movement of the TM during the next 100-year in the soil under different PS doses (80 and 40m3ha-1cultivation-1) and tillage frequencies (no-tillage and 20, 10, and 5-year tillage). No-tillage simulations revealed consistent TM surface accumulations, reaching the soil threshold value for Cu in the 0-20cm layer after 86 years of PS amendments at high doses, but in layers 0-5, 0-10, and 5-10cm, this concentration was already reached after 17, 38, and 75 years, respectively. While soil tillage reduced TM concentrations over the top 20cm of the soil profile, it increased their transfer to deeper layers. Periodical soil tillage each 5, 10, and 20 years was found to allow PS applications without reaching the Cu threshold value in soil during 100 years. However, soil solution concentrations of Zn reached the threshold values for groundwater. Therefore, the best manure management practice for the long-term PS disposal with respect to Zn and Cu concentrations in soil is the application of moderate PS rates. © 2014 Elsevier B.V.

Published
2014

7. Characterization of microparticles derived from waste plastics and their bio-interaction with human lung A549 cells

Author

Bengalli, R, Zerboni, A, Bonfanti, P, Saibene, M, Mehn, D, Cella, C, Ponti, J, La Spina, R, Mantecca, P, Bengalli R., Zerboni A., Bonfanti P., Saibene M., Mehn D., Cella C., Ponti J., La Spina R., Mantecca P., Bengalli, R, Zerboni, A, Bonfanti, P, Saibene, M, Mehn, D, Cella, C, Ponti, J, La Spina, R, Mantecca, P, Bengalli R., Zerboni A., Bonfanti P., Saibene M., Mehn D., Cella C., Ponti J., La Spina R., and Mantecca P.

Published
2022

8. Multimodal treatment for resectable neuroendocrine carcinoma of the cervix

Author

Valenza, C, Spada, F, Multinu, F, Benini, L, Borghesani, M, Algeri, L, Rubino, M, Pisa, E, Gervaso, L, Cella, C, Carinelli, S, Bruni, S, Schivardi, G, Curigliano, G, Zanagnolo, V, Aletti, G, Colombo, N, Fazio, N, Valenza, Carmine, Spada, Francesca, Multinu, Francesco, Benini, Lavinia, Borghesani, Michele, Algeri, Laura, Rubino, Manila, Pisa, Eleonora, Gervaso, Lorenzo, Cella, Chiara Alessandra, Carinelli, Silvestro, Bruni, Simone, Schivardi, Gabriella, Curigliano, Giuseppe, Zanagnolo, Vanna, Aletti, Giovanni, Colombo, Nicoletta, Fazio, Nicola, Valenza, C, Spada, F, Multinu, F, Benini, L, Borghesani, M, Algeri, L, Rubino, M, Pisa, E, Gervaso, L, Cella, C, Carinelli, S, Bruni, S, Schivardi, G, Curigliano, G, Zanagnolo, V, Aletti, G, Colombo, N, Fazio, N, Valenza, Carmine, Spada, Francesca, Multinu, Francesco, Benini, Lavinia, Borghesani, Michele, Algeri, Laura, Rubino, Manila, Pisa, Eleonora, Gervaso, Lorenzo, Cella, Chiara Alessandra, Carinelli, Silvestro, Bruni, Simone, Schivardi, Gabriella, Curigliano, Giuseppe, Zanagnolo, Vanna, Aletti, Giovanni, Colombo, Nicoletta, and Fazio, Nicola

Abstract

Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy, and discussed at the European Institute of Oncology's Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient preferences.

Published
2023

9. Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal

Author

Gervaso, L, Pellicori, S, Cella, C, Bagnardi, V, Lordick, F, Fazio, N, Gervaso L., Pellicori S., Cella C. A., Bagnardi V., Lordick F., Fazio N., Gervaso, L, Pellicori, S, Cella, C, Bagnardi, V, Lordick, F, Fazio, N, Gervaso L., Pellicori S., Cella C. A., Bagnardi V., Lordick F., and Fazio N.

Abstract

Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial.

Published
2021

11. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients

Author

Schorling, R. M., Pfrepper, C., Golombek, T., Cella, C. A., Munoz-Unceta, N., Siegemund, R., Engel, C., Petros, S., Lordick, F., and Knodler, M.

Subjects
Male, Cancer Research, medicine.medical_specialty, Biomarkers, Cholangiocarcinoma, D-dimer, Risk assessment models, Venous thromboembolism, Antineoplastic Agents, Risk Assessment, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, Venous thromboembolism, Biomarkers, D-dimer, Risk assessment models, Cholangiocarcinoma, 0302 clinical medicine, Neoplasms, Internal medicine, Ambulatory Care, medicine, Humans, Prospective Studies, ddc:610, cardiovascular diseases, 030212 general & internal medicine, Mean platelet volume, Aged, business.industry, Thrombin, Cancer, Venous Thromboembolism, Hematology, Middle Aged, equipment and supplies, medicine.disease, Thrombosis, P-Selectin, Oncology, 030220 oncology & carcinogenesis, Ambulatory, Biomarker (medicine), Female, business, Complication, Risk assessment, Mean Platelet Volume
Abstract

Background: Venous thromboembolism (VTE) is a common complication of cancer. This study aimed to evaluate immature platelet fraction (IPF), mean platelet volume (MPV), P-selectin, D-dimer, and thrombin generation (TG) as predictive biomarkers for VTE and further the improvement of existing risk assessment models (RAMs). Methods: A prospective, observational, exploratory study was conducted on ambulatory cancer patients with indication for systemic chemotherapy. Baseline RAMs included the Khorana-, Vienna Cancer, Thrombosis-, Protecht-, ONKOTEV-, and Catscore. IPF, MPV, P-selectin, D-dimer, and TG were analysed at baseline and 3-month follow-up. Results: We enrolled 100 patients, of whom 89 completed the follow-up. Frequent tumour types were breast (30%), gastric (14%), gynaecological (14%), and colorectal (14%) cancer. Ten of the 89 patients (11.2%) developed VTE. The highest VTE rate was observed in patients with cholangiocarcinoma (3/5; 60%). Baseline D-dimer levels but not IPF, MPV, or P-selectin were associated with the risk of developing VTE (HR 6.9; p = 0.021). None of the RAMs showed statistical significance in predicting VTE. Peak thrombin and endogenous thrombin potential were lower in patients who developed VTE. Biomarker changes between baseline and follow-up were not associated with VTE risk. Conclusions: VTE risk was well predicted by baseline D-dimer levels. Adding D-dimer could improve existing RAMs to better identify patients who may benefit from primary VTE prophylaxis. The VTE risk among patients with cholangiocarcinoma should be further evaluated.

Published
2020
Full Text
View/download PDF

12. Microplastics from miscellaneous plastic wastes: Physico-chemical characterization and impact on fish and amphibian development

Author

Bonfanti, P, Colombo, A, Saibene, M, Motta, G, Saliu, F, Catelani, T, Mehn, D, La Spina, R, Ponti, J, Cella, C, Floris, P, Mantecca, P, Bonfanti, Patrizia, Colombo, Anita, Saibene, Melissa, Motta, Giulia, Saliu, Francesco, Catelani, Tiziano, Mehn, Dora, La Spina, Rita, Ponti, Jessica, Cella, Claudia, Floris, Pamela, Mantecca, Paride, Bonfanti, P, Colombo, A, Saibene, M, Motta, G, Saliu, F, Catelani, T, Mehn, D, La Spina, R, Ponti, J, Cella, C, Floris, P, Mantecca, P, Bonfanti, Patrizia, Colombo, Anita, Saibene, Melissa, Motta, Giulia, Saliu, Francesco, Catelani, Tiziano, Mehn, Dora, La Spina, Rita, Ponti, Jessica, Cella, Claudia, Floris, Pamela, and Mantecca, Paride

Abstract

Microplastic pollution represents a global problem with negative impacts on aquatic environment and organisms' health. To date, most of the laboratory toxicological studies on microplastics (MPs) have made use of single commercial micro and nano-polymers, which do not reflect the heterogeneity of environmental MPs. To improve the relevance of the hazard assessment, micrometer-sized plastic particles of miscellaneous non-reusable waste plastics, with size <100 mu m and <50 mu m (waste microplastics, wMPs), were characterized by microscopic and spectroscopic techniques and tested on developing zebrafish and Xenopus laevis by FET and FETAX assays respectively. Moreover, the modalities of wMP interaction with the embryonic structures, as well as the histological lesions, were explored by light and electron microscopy. We have shown that wMPs had very heterogeneous shapes and sizes, were mainly composed of polyethylene and polypropylene and contained metal and organic impurities, as well as submicrometric particle fractions, features that resemble those of environmental occurring MPs. wMPs (0.1-100 mg/L) caused low rate of mortality and altered phenotypes in embryos, but established species-specific biointeractions. In zebrafish, wMPs by adhering to chorion were able to delay hatching in a size and concentration dependent manner. In Xenopus embryos, which open stomodeum earlier than zebrafish, wMPs were accumulated in intestinal tract, where produced mechanical stress and stimulated mucus overproduction, attesting an irritation response. Although wMP biointeractions did not interfere with morphogenesis processes, further studies are needed to understand the underlying mechanisms and long-term impact of these, or even smaller, wMPs.

Published
2021

13. O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study

Author

Smyth, E., Mauer, M., Cella, C., Ben-Aharon, I., Piessen, G., Wyrwicz, L., Al-Haidari, G., Kanonnikoff, T. Fleitas, Boige, V., Stahl, M., Martens, U., Obermannová, R., Gomez-Martin, C., Thuss-Patience, P., Arrazubi, V., Avallone, A., Shiu, K., Collienne, M., Giraut, A., and Lordick, F.

Published
2023
Full Text
View/download PDF

15. High copper content in vineyard soils promotes modifications in photosynthetic parameters and morphological changes in the root system of 'Red Niagara' plantlets

Author

AMBROSINI V. G, ROSA D. J., BASTOS DE MELO G. W., ZALAMENA J., CELLA C., SIMAO D. G., SOUZA DA SILVA L., PESSOA DOS SANTOS H., TOSELLI M., TIECHER T. L., BRUNETTO G., and AMBROSINI V.G, AMBROSINI V.G, ROSA D.J., BASTOS DE MELO G.W., ZALAMENA J., CELLA C., SIMAO D.G., SOUZA DA SILVA L., PESSOA DOS SANTOS H., TOSELLI M., TIECHER T.L., BRUNETTO G.

Subjects
0106 biological sciences, Farms, Physiology, Plant Science, Root system, 010501 environmental sciences, Photosynthesis, Plant Roots, 01 natural sciences, Vineyard, Available Cu Net photosynthesis Maximum quantum yield Root diameter Vitis labrusca L, Soil, chemistry.chemical_compound, Nutrient, Genetics, Vitis, 0105 earth and related environmental sciences, Transpiration, Photosystem II Protein Complex, Plant Transpiration, Horticulture, chemistry, Chlorophyll, Shoot, Soil water, Copper, 010606 plant biology & botany
Abstract

High copper (Cu) soil contents, due to the continuous vineyard application of Cu fungicides throughout the years, may impair the growth of the shoot and modify the structure of the root system. The current study aimed to investigate the threshold levels of available Cu in the soil causing toxicity effects in young grapevine plants of ‘Red Niagara’ cultivated in clay soils. Grapevine plantlets were cultivated in pots containing vineyard devoted soils with increasing contents of available Cu (25, 80, 100 and 165 mg kg−1), for 53 days. Photosynthesis and transpiration rates, and the quantum yield of photosystem II (Fv/Fm) were evaluated during the cultivation period. At the end of the experiment, the plant nutrient and leaf chlorophyll were determined, along with the anatomical analysis of the root system structure and plant dry matter determination. Higher levels of available Cu in the soil increased the apoplastic, symplastic and total fraction of the metal in the roots, reducing the other nutrients, especially in the shoots. Photosynthesis, transpiration rates and Fv/Fm were also reduced. Higher levels of Cu led to anatomical changes in the roots, that increased diameter, number of layers in the cortex, vascular cylinder and total root areas. It also resulted in reduced dry matter production by grapevines.

Published
2018

16. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

Author

Mulder, Frits I. Candeloro, Matteo Kamphuisen, Pieter W. Di Nisio, Marcello Bossuyt, Patrick M. Guman, Noori Smit, Kirsten Buller, Harry R. van Es, Nick Abdel-Razeq, H. and Ades, S. Ayappan, S. R. Borchmann, S. Cella, C. A. and Fankhauser, C. D. Ferroni, P. Fuentes, H. E. Kruger, S. and Lim, S. H. Lubberts, S. Lustig, D. B. Mansfield, A. S. and Munoz Martin, A. J. Noble, S. Panizo, E. Papaxoinis, G. and Park, K. Patel, J. N. Posch, F. Ramos, J. D. Roselli, M. and Santi, R. Sohal, D. Srikanthan, A. Tafur, A. J. and Terbuch, A. Thomas, M. Vathiotis, O. Wang, R. Zahir, M. N. CAT-prediction Collaborators

Abstract

We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were searched from January 2008 to June 2018 for studies which evaluated the Khorana score. Two authors independently screened studies for eligibility, extracted data, and assessed risk of bias. Additional data on the 6-month incidence of venous thromboembolism were sought by contacting corresponding authors. The incidence in each Khorana score risk group was estimated with random effects meta-analysis. A total of 45 articles and eight abstracts were included, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For 27,849 patients (81%), 6-month follow-up data were obtained. Overall, 19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2 points, and 17% a score of 3 or more points. The incidence of venous thromboembolism in the first six months was 5.0% (95% CI: 3.9-6.5) in patients with a low-risk Khorana score (0 points), 6.6% (95% CI: 5.6-7.7) in those with an intermediate-risk Khorana score (1 or 2 points), and 11.0% (95% CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or higher). Of the patients with venous thromboembolism in the first six months, 23.4% (95% CI: 18.4-29.4) had been classified as high risk according to the Khorana score. In conclusion, the Khorana score can be used to select ambulatory cancer patients at high risk of venous thromboembolism for thromboprophylaxis; however, most events occur outside this high-risk group.

Published
2019

17. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

Author

Mulder, Fi, Candeloro, M, Kamphuisen, Pw, Di Nisio, M, Bossuyt, Pm, Guman, N, Smit, K, Büller, Hr, van Es, N, Abdel-Razeq, H, Ades, S, Ayappan, S, Borchman, S, Cella, C, Fankhauser, C, Ferroni, P, Fuentes, H, Kruger, S, Lim, S, Lubberts, S, Lustig, D, Mansfield, A, Munoz-Martin, A, Noble, S, Panizo, E, Papaxoinis, G, Park, K, Patel, J, Posch, F, Ramos, J, Roselli, M, Fiumara, Sr, Srikanthan, A, Tafur, A, Terbuch, A, Thomas, M, Vathiotis, O, Wang, R, Zahir, M, Sohal, D, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ACS - Amsterdam Cardiovascular Sciences, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, Intensive Care Medicine, and ACS - Atherosclerosis & ischemic syndromes

Subjects
Male, medicine.medical_specialty, PULMONARY-EMBOLISM, Settore MED/06 - Oncologia Medica, cancer-associated venous thromboembolism, D-DIMER, Severity of Illness Index, Article, EVENTS, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, D-dimer, Severity of illness, medicine, Humans, Clinical significance, ADVANCED PANCREATIC-CANCER, CLINICAL-SIGNIFICANCE, Venous Thrombosis, Blood Coagulation and Fibrinolysis, RISK PREDICTION, business.industry, Incidence, Incidence (epidemiology), Coagulation & Its Disorders, AMBULATORY PATIENTS, PATIENTS RECEIVING CHEMOTHERAPY, Venous Thromboembolism, Hematology, Publication bias, MOLECULAR-WEIGHT HEPARIN, Prognosis, medicine.disease, Pulmonary embolism, Meta-analysis, Ambulatory, Female, Disease Susceptibility, VTE, Disorders of Coagulation and Fibrinolysis, business, Publication Bias, 030215 immunology
Abstract

We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were searched from January 2008 to June 2018 for studies which evaluated the Khorana score. Two authors independently screened studies for eligibility, extracted data, and assessed risk of bias. Additional data on the 6-month incidence of venous thromboembolism were sought by contacting corresponding authors. The incidence in each Khorana score risk group was estimated with random effects meta-analysis. A total of 45 articles and eight abstracts were included, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For 27,849 patients (81%), 6-month follow-up data were obtained. Overall, 19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2 points, and 17% a score of 3 or more points. The incidence of venous thromboembolism in the first six months was 5.0% (95% CI: 3.9-6.5) in patients with a low-risk Khorana score (0 points), 6.6% (95% CI: 5.6-7.7) in those with an intermediate-risk Khorana score (1 or 2 points), and 11.0% (95% CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or higher). Of the patients with venous thromboembolism in the first six months, 23.4% (95% CI: 18.4-29.4) had been classified as high risk according to the Khorana score. In conclusion, the Khorana score can be used to select ambulatory cancer patients at high risk of venous thromboembolism for thromboprophylaxis; however, most events occur outside this high-risk group.

Published
2019

18. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

Author

Mulder, Frits I., Candeloro, Matteo, Kamphuisen, Pieter W., Di Nisio, Marcello, Bossuyt, Patrick M., Guman, Noori, Smit, Kirsten, Buller, Harry R., van Es, Nick, Abdel-Razeq, H., Ades, S., Ayappan, S. R., Borchmann, S., Cella, C. A., Fankhauser, C. D., Ferroni, P., Fuentes, H. E., Kruger, S., Lim, S. H., Lubberts, S., Lustig, D. B., Mansfield, A. S., Munoz Martin, A. J., Noble, S., Panizo, E., Papaxoinis, G., Park, K., Patel, J. N., Posch, F., Ramos, J. D., Roselli, M., Santi, R., Sohal, D., Srikanthan, A., Tafur, A. J., Terbuch, A., Thomas, M., Vathiotis, O., Wang, R., Zahir, M. N., Mulder, Frits I., Candeloro, Matteo, Kamphuisen, Pieter W., Di Nisio, Marcello, Bossuyt, Patrick M., Guman, Noori, Smit, Kirsten, Buller, Harry R., van Es, Nick, Abdel-Razeq, H., Ades, S., Ayappan, S. R., Borchmann, S., Cella, C. A., Fankhauser, C. D., Ferroni, P., Fuentes, H. E., Kruger, S., Lim, S. H., Lubberts, S., Lustig, D. B., Mansfield, A. S., Munoz Martin, A. J., Noble, S., Panizo, E., Papaxoinis, G., Park, K., Patel, J. N., Posch, F., Ramos, J. D., Roselli, M., Santi, R., Sohal, D., Srikanthan, A., Tafur, A. J., Terbuch, A., Thomas, M., Vathiotis, O., Wang, R., and Zahir, M. N.

Abstract

We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were searched from January 2008 to June 2018 for studies which evaluated the Khorana score. Two authors independently screened studies for eligibility, extracted data, and assessed risk of bias. Additional data on the 6-month incidence of venous thromboembolism were sought by contacting corresponding authors. The incidence in each Khorana score risk group was estimated with random effects meta-analysis. A total of 45 articles and eight abstracts were included, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For 27,849 patients (81%), 6-month follow-up data were obtained. Overall, 19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2 points, and 17% a score of 3 or more points. The incidence of venous thromboembolism in the first six months was 5.0% (95% CI: 3.9-6.5) in patients with a low-risk Khorana score (0 points), 6.6% (95% CI: 5.6-7.7) in those with an intermediate-risk Khorana score (1 or 2 points), and 11.0% (95% CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or higher). Of the patients with venous thromboembolism in the first six months, 23.4% (95% CI: 18.4-29.4) had been classified as high risk according to the Khorana score. In conclusion, the Khorana score can be used to select ambulatory cancer patients at high risk of venous thromboembolism for thromboprophylaxis; however, most events occur outside this high-risk group.

Published
2019

19. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus

Author

Ruggenenti, P, Lauria, G, Iliev, IP, Fassi, A, Ilieva, AP, Rota, S, Chiurchiu, C, Barlovic, DP, Sghirlanzoni, A, Lombardi, R, Penza, P, CAVALETTI, GUIDO ANGELO, Piatti, ML, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, AR, TREVISAN, ROBERTO, Remuzzi, G, DEMAND Study Investigators, Parvanova, IA, Petrov, II, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Cavaletti, G, Marzorati, L, MARMIROLI, PAOLA LORENA, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, GA, Ganeva, M, Cannata, AN, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, Gardini, F, Lauria, G., Ruggenenti, P, Lauria, G, Iliev, I, Fassi, A, Ilieva, A, Rota, S, Chiurchiu, C, Barlovic, D, Sghirlanzoni, A, Lombardi, R, Penza, P, Cavaletti, G, Piatti, M, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, A, Trevisan, R, Remuzzi, G, DEMAND Study, I, Parvanova, I, Petrov, I, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Marzorati, L, Marmiroli, P, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, G, Ganeva, M, Cannata, A, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, and Gardini, F

Subjects
Adult, Blood Glucose, Male, Dihydropyridines, medicine.medical_specialty, Diabetic neuropathy, Urology, Renal function, Delapril, Angiotensin-Converting Enzyme Inhibitors, Kidney Function Tests, Placebo, Risk Assessment, Severity of Illness Index, Drug Administration Schedule, Piperazines, Body Mass Index, Manidipine, Double-Blind Method, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Diabetic Nephropathies, Nitrobenzenes, Aged, Dose-Response Relationship, Drug, diabetes, business.industry, Hazard ratio, Middle Aged, Calcium Channel Blockers, Prognosis, medicine.disease, Survival Rate, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, Hypertension, Indans, Albuminuria, Drug Therapy, Combination, Female, medicine.symptom, business, medicine.drug
Abstract

To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria 2 (IQR: 0.16–0.50 mL/min per 1.73 m 2 ) on combined therapy, 0.36 mL/min per 1.73 m 2 (IQR: 0.18–0.53 mL/min per 1.73 m 2 ) on delapril, and 0.30 mL/min per 1.73 m 2 (IQR: 0.12–0.50 mL/min per 1.73 m 2 ) on placebo ( P =0.87 and P =0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04–0.78; P =0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07–0.99; P =0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24–0.87; P =0.017) and 0.52 (0.27–0.99; P =0.048), respectively. Glucose disposal rate decreased from 5.8±2.4 to 5.3±1.9 mg/kg per min on placebo ( P =0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity.

Published
2011
Full Text
View/download PDF

20. High copper content in vineyard soils promotes modifications in photosynthetic parameters and morphological changes in the root system of 'Red Niagara' plantlets

Author

AMBROSINI, V. G., ROSA, D. J., MELO, G. W. B. de, ZALAMENA, J., CELLA, C., SIMÃO, D. G., SILVA, L. S. da, SANTOS, H. P. dos, TOSELLI, M., TIECHER, T. L., BRUNETTO, G., Vítor Gabriel Ambrosini, Departamento de Solos, Faculdade de Agronomia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul (RS), Brazil, Daniel José Rosa, Departamento de Fitotecnia, Centro de Ciências Agrárias, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Santa Catarina (SC), Brazil, GEORGE WELLINGTON BASTOS DE MELO, CNPUV, Jovani Zalamena, Centro Nacional de Pesquisa de Uva e Vinho, Empresa Brasileira de Pesquisa Agropecuária (Embrapa), Bento Gonçalves, RS, Brazil, Cesar Cella, Departamento de Solos, Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil, Daniela Guimarães Simão, Departamento de Biologia, Centro de Ciências Naturais e Exatas, UFSM, RS, Brazil, Leandro Souza da Silva, Departamento de Solos, Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil, HENRIQUE PESSOA DOS SANTOS, CNPUV, Moreno Toselli, Dipartimento di Scienze Agrarie, Università di Bologna, Bologna, Italy, Tadeu Luis Tiecher, Instituto Federal Farroupilha (IFFar), Campus Alegrete, Alegrete, Brazil, and Gustavo Brunetto, Departamento de Solos, Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil.

Subjects
Available Cu, Net photosynthesis, Root diameter, Vitis labrusca L, Maximum quantum yield, Root systems, High copper, ‘Red Niagara’ plantlets, Vineyard soils
Abstract

High copper (Cu) soil contents, due to the continuous vineyard application of Cu fungicides throughout the years, may impair the growth of the shoot and modify the structure of the root system. The current study aimed to investigate the threshold levels of available Cu in the soil causing toxicity effects in young grapevine plants of ‘Red Niagara’ cultivated in clay soils. Grapevine plantlets were cultivated in pots containing vineyard devoted soils with increasing contents of available Cu (25, 80, 100 and 165 mg kg?1 ), for 53 days. Photosynthesis and transpiration rates, and the quantum yield of photosystem II (Fv/Fm) were evaluated during the cultivation period. At the end of the experiment, the plant nutrient and leaf chlorophyll were determined, along with the anatomical analysis of the root system structure and plant dry matter determination. Higher levels of available Cu in the soil increased the apoplastic, symplastic and total fraction of the metal in the roots, reducing the other nutrients, especially in the shoots. Photosynthesis, transpiration rates and Fv/Fm were also reduced. Higher levels of Cu led to anatomical changes in the roots, that increased diameter, number of layers in the cortex, vascular cylinder and total root areas. It also resulted in reduced dry matter production by grapevines. Keywords: Available Cu Net photosynthesis Maximum quantum yield Root diameter Vitis labrusca L Made available in DSpace on 2019-01-11T00:04:58Z (GMT). No. of bitstreams: 1 Highcoppercontentinvineyardsoilspromotesmodi64257cationsin.pdf: 1434017 bytes, checksum: 77453d1f9f03c8da1881ad6ee30af116 (MD5) Previous issue date: 2019-01-09

Published
2018

21. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

Author

Gaspari, F, Ruggenenti, P, Porrini, E, Motterlini, N, Cannata, A, Carrara, F, Sosa, A, Cella, C, Ferrari, S, Stucchi, N, Parvanova, A, Iliev, I, Trevisan, R, Bossi, A, Zaletel, J, Remuzzi, G, Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, Sosa AJ, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Trevisan R, Bossi A, Zaletel J, Remuzzi G, Gaspari, F, Ruggenenti, P, Porrini, E, Motterlini, N, Cannata, A, Carrara, F, Sosa, A, Cella, C, Ferrari, S, Stucchi, N, Parvanova, A, Iliev, I, Trevisan, R, Bossi, A, Zaletel, J, Remuzzi, G, Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, Sosa AJ, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Trevisan R, Bossi A, Zaletel J, and Remuzzi G

Abstract

There are no adequate studies that have formally tested the performance of different estimating formulas in patients with type 2 diabetes both with and without overt nephropathy. Here we evaluated the agreement between baseline GFRs, GFR changes at month 6, and long-term GFR decline measured by iohexol plasma clearance or estimated by 15 creatinine-based formulas in 600 type 2 diabetics followed for a median of 4.0 years. Ninety patients were hyperfiltering. The number of those identified by estimation formulas ranged from 0 to 24:58 were not identified by any formula. Baseline GFR was significantly underestimated and a 6-month GFR reduction was missed in hyperfiltering patients. Long-term GFR decline was also underestimated by all formulas in the whole study group and in hyper-, normo-, and hypofiltering patients considered separately. Five formulas generated positive slopes in hyperfiltering patients. Baseline concordance correlation coefficients and total deviation indexes ranged from 32.1% to 92.6% and from 0.21 to 0.53, respectively. Concordance correlation coefficients between estimated and measured long-term GFR decline ranged from -0.21 to 0.35. The agreement between estimated and measured values was also poor within each subgroup considered separately. Thus, our study questions the use of any estimation formula to identify hyperfiltering patients and monitor renal disease progression and response to treatment in type 2 diabetics without overt nephropathy.

Published
2013

22. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study

Author

Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Prandini S, Ene Iordache B, Diadei O, Perico N, Ondei P, Buongiorno E, Messa P, Dugo M, Remuzzi G, GFR ADPKD Study Group, PISANI, ANTONIO, Ruggenenti, P, Gaspari, F, Cannata, A, Carrara, F, Cella, C, Ferrari, S, Stucchi, N, Prandini, S, Ene Iordache, B, Diadei, O, Perico, N, Ondei, P, Pisani, Antonio, Buongiorno, E, Messa, P, Dugo, M, Remuzzi, G, and GFR ADPKD Study, Group

Subjects
Nephrology, Adult, Male, medicine.medical_specialty, Anatomy and Physiology, Clinical Research Design, Iohexol, Science, Urology, Autosomal dominant polycystic kidney disease, Renal function, urologic and male genital diseases, Cohort Studies, chemistry.chemical_compound, Internal medicine, medicine, Polycystic kidney disease, Humans, Biology, Creatinine, Multidisciplinary, Models, Statistical, business.industry, urogenital system, Reproducibility of Results, Renal System, Middle Aged, medicine.disease, Polycystic Kidney, Autosomal Dominant, female genital diseases and pregnancy complications, Endocrinology, Treatment Outcome, chemistry, Research Design, Disease Progression, Medicine, Female, sense organs, business, medicine.drug, Kidney disease, Cohort study, Research Article, Glomerular Filtration Rate
Abstract

Trials failed to demonstrate protective effects of investigational treatments on glomerular filtration rate (GFR) reduction in Autosomal Dominant Polycystic Kidney Disease (ADPKD). To assess whether above findings were explained by unreliable GFR estimates, in this academic study we compared GFR values centrally measured by iohexol plasma clearance with corresponding values estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) and abbreviated Modification of Diet in Renal Disease (aMDRD) formulas in ADPKD patients retrieved from four clinical trials run by a Clinical Research Center and five Nephrology Units in Italy. Measured baseline GFRs and one-year GFR changes averaged 78.6±26.7 and 8.4±10.3 mL/min/1.73 m(2) in 111 and 71 ADPKD patients, respectively. CKD-Epi significantly overestimated and aMDRD underestimated baseline GFRs. Less than half estimates deviated by

Published
2012

24. Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis

Author

Silvestris, N., primary, Brunetti, O., additional, Marchetti, P., additional, Mazzuca, F., additional, Vasile, E., additional, Gelsomino, F., additional, Zanon, S., additional, Giardini Casadei, A., additional, Milella, M., additional, Basile, D., additional, Barni, S., additional, Scartozzi, M., additional, Laffi, A., additional, Delfanti, S., additional, Cella, C., additional, De Vita, F., additional, Giusi, G., additional, Lorusso, V., additional, Scarpa, A., additional, and Cascinu, S., additional

Published
2016
Full Text
View/download PDF

27. Bevacizumab-induced hypertension is a predictive marker of response and progression free survival in patients treated for metastatic colorectal cancer

Author

DE STEFANO, A., Carlomagno, C., Cannella, L., Crispo, A., Pepe, Stefano, Alfieri, S., Colantuoni, M., Cella, C., Raimondo, L., DE PLACIDO, S., DE STEFANO, Alfonso, Carlomagno, Chiara, L., Cannella, A., Crispo, S., Pepe, S., Alfieri, M., Colantuoni, Ac, Cella, L., Raimondo, and DE PLACIDO, Sabino

Subjects
predictive factor, colorectal, hypertension, bevacizumab
Published
2009

28. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Author

Vos, T, Flaxman, AD, Naghavi, M, Lozano, R, Michaud, C, Ezzati, M, Shibuya, K, Salomon, JA, Abdalla, S, Aboyans, V, Abraham, J, Ackerman, I, Aggarwal, R, Ahn, SY, Ali, MK, Alvarado, M, Anderson, HR, Anderson, LM, Andrews, KG, Atkinson, C, Baddour, LM, Bahalim, AN, Barker-Collo, S, Barrero, LH, Bartels, DH, Basanez, M-G, Baxter, A, Bell, ML, Benjamin, EJ, Bennett, D, Bernabe, E, Bhalla, K, Bhandari, B, Bikbov, B, Bin Abdulhak, A, Birbeck, G, Black, JA, Blencowe, H, Blore, JD, Blyth, F, Bolliger, I, Bonaventure, A, Boufous, SA, Bourne, R, Boussinesq, M, Braithwaite, T, Brayne, C, Bridgett, L, Brooker, S, Brooks, P, Brugha, TS, Bryan-Hancock, C, Bucello, C, Buchbinder, R, Buckle, GR, Budke, CM, Burch, M, Burney, P, Burstein, R, Calabria, B, Campbell, B, Canter, CE, Carabin, H, Carapetis, J, Carmona, L, Cella, C, Charlson, F, Chen, H, Cheng, AT-A, Chou, D, Chugh, SS, Coffeng, LE, Colan, SD, Colquhoun, S, Colson, KE, Condon, J, Connor, MD, Cooper, LT, Corriere, M, Cortinovis, M, de Vaccaro, KC, Couser, W, Cowie, BC, Criqui, MH, Cross, M, Dabhadkar, KC, Dahiya, M, Dahodwala, N, Damsere-Derry, J, Danaei, G, Davis, A, De Leo, D, Degenhardt, L, Dellavalle, R, Delossantos, A, Denenberg, J, Derrett, S, Des Jarlais, DC, Dharmaratne, SD, Dherani, M, Diaz-Torne, C, Dolk, H, Dorsey, ER, Driscoll, T, Duber, H, Ebel, B, Edmond, K, Elbaz, A, Ali, SE, Erskine, H, Erwin, PJ, Espindola, P, Ewoigbokhan, SE, Farzadfar, F, Feigin, V, Felson, DT, Ferrari, A, Ferri, CP, Fevre, EM, Finucane, MM, Flaxman, S, Flood, L, Foreman, K, Forouzanfar, MH, Fowkes, FGR, Franklin, R, Fransen, M, Freeman, MK, Gabbe, BJ, Gabriel, SE, Gakidou, E, Ganatra, HA, Garcia, B, Gaspari, F, Gillum, RF, Gmel, G, Gosselin, R, Grainger, R, Groeger, J, Guillemin, F, Gunnell, D, Gupta, R, Haagsma, J, Hagan, H, Halasa, YA, Hall, W, Haring, D, Maria Haro, J, Harrison, JE, Havmoeller, R, Hay, RJ, Higashi, H, Hill, C, Hoen, B, Hoffman, H, Hotez, PJ, Hoy, D, Huang, JJ, Ibeanusi, SE, Jacobsen, KH, James, SL, Jarvis, D, Jasrasaria, R, Jayaraman, S, Johns, N, Jonas, JB, Karthikeyan, G, Kassebaum, N, Kawakami, N, Keren, A, Khoo, J-P, King, CH, Knowlton, LM, Kobusingye, O, Koranteng, A, Krishnamurthi, R, Lalloo, R, Laslett, LL, Lathlean, T, Leasher, JL, Lee, YY, Leigh, J, Lim, SS, Limb, E, Lin, JK, Lipnick, M, Lipshultz, SE, Liu, W, Loane, M, Ohno, SL, Lyons, R, Ma, J, Mabweijano, J, MacIntyre, MF, Malekzadeh, R, Mallinger, L, Manivannan, S, Marcenes, W, March, L, Margolis, DJ, Marks, GB, Marks, R, Matsumori, A, Matzopoulos, R, Mayosi, BM, McAnulty, JH, McDermott, MM, McGill, N, McGrath, J, Elena Medina-Mora, M, Meltzer, M, Mensah, GA, Merriman, TR, Meyer, A-C, Miglioli, V, Miller, M, Miller, TR, Mitchell, PB, Mocumbi, AO, Moffitt, TE, Mokdad, AA, Monasta, L, Montico, M, Moradi-Lakeh, M, Moran, A, Morawska, L, Mori, R, Murdoch, ME, Mwaniki, MK, Naidoo, K, Nair, MN, Naldi, L, Narayan, KMV, Nelson, PK, Nelson, RG, Nevitt, MC, Newton, CR, Nolte, S, Norman, P, Norman, R, O'Donnell, M, O'Hanlon, S, Olives, C, Omer, SB, Ortblad, K, Osborne, R, Ozgediz, D, Page, A, Pahari, B, Pandian, JD, Rivero, AP, Patten, SB, Pearce, N, Perez Padilla, R, Perez-Ruiz, F, Perico, N, Pesudovs, K, Phillips, D, Phillips, MR, Pierce, K, Pion, S, Polanczyk, GV, Polinder, S, Pope, CA, Popova, S, Porrini, E, Pourmalek, F, Prince, M, Pullan, RL, Ramaiah, KD, Ranganathan, D, Razavi, H, Regan, M, Rehm, JT, Rein, DB, Remuzzi, G, Richardson, K, Rivara, FP, Roberts, T, Robinson, C, De Leon, FR, Ronfani, L, Room, R, Rosenfeld, LC, Rushton, L, Sacco, RL, Saha, S, Sampson, U, Sanchez-Riera, L, Sanman, E, Schwebel, DC, Scott, JG, Segui-Gomez, M, Shahraz, S, Shepard, DS, Shin, H, Shivakoti, R, Singh, D, Singh, GM, Singh, JA, Singleton, J, Sleet, DA, Sliwa, K, Smith, E, Smith, JL, Stapelberg, NJC, Steer, A, Steiner, T, Stolk, WA, Stovner, LJ, Sudfeld, C, Syed, S, Tamburlini, G, Tavakkoli, M, Taylor, HR, Taylor, JA, Taylor, WJ, Thomas, B, Thomson, WM, Thurston, GD, Tleyjeh, IM, Tonelli, M, Towbin, JRA, Truelsen, T, Tsilimbaris, MK, Ubeda, C, Undurraga, EA, van der Werf, MJ, van Os, J, Vavilala, MS, Venketasubramanian, N, Wang, M, Wang, W, Watt, K, Weatherall, DJ, Weinstock, MA, Weintraub, R, Weisskopf, MG, Weissman, MM, White, RA, Whiteford, H, Wiersma, ST, Wilkinson, JD, Williams, HC, Williams, SRM, Witt, E, Wolfe, F, Woolf, AD, Wulf, S, Yeh, P-H, Zaidi, AKM, Zheng, Z-J, Zonies, D, Lopez, AD, Murray, CJL, Vos, T, Flaxman, AD, Naghavi, M, Lozano, R, Michaud, C, Ezzati, M, Shibuya, K, Salomon, JA, Abdalla, S, Aboyans, V, Abraham, J, Ackerman, I, Aggarwal, R, Ahn, SY, Ali, MK, Alvarado, M, Anderson, HR, Anderson, LM, Andrews, KG, Atkinson, C, Baddour, LM, Bahalim, AN, Barker-Collo, S, Barrero, LH, Bartels, DH, Basanez, M-G, Baxter, A, Bell, ML, Benjamin, EJ, Bennett, D, Bernabe, E, Bhalla, K, Bhandari, B, Bikbov, B, Bin Abdulhak, A, Birbeck, G, Black, JA, Blencowe, H, Blore, JD, Blyth, F, Bolliger, I, Bonaventure, A, Boufous, SA, Bourne, R, Boussinesq, M, Braithwaite, T, Brayne, C, Bridgett, L, Brooker, S, Brooks, P, Brugha, TS, Bryan-Hancock, C, Bucello, C, Buchbinder, R, Buckle, GR, Budke, CM, Burch, M, Burney, P, Burstein, R, Calabria, B, Campbell, B, Canter, CE, Carabin, H, Carapetis, J, Carmona, L, Cella, C, Charlson, F, Chen, H, Cheng, AT-A, Chou, D, Chugh, SS, Coffeng, LE, Colan, SD, Colquhoun, S, Colson, KE, Condon, J, Connor, MD, Cooper, LT, Corriere, M, Cortinovis, M, de Vaccaro, KC, Couser, W, Cowie, BC, Criqui, MH, Cross, M, Dabhadkar, KC, Dahiya, M, Dahodwala, N, Damsere-Derry, J, Danaei, G, Davis, A, De Leo, D, Degenhardt, L, Dellavalle, R, Delossantos, A, Denenberg, J, Derrett, S, Des Jarlais, DC, Dharmaratne, SD, Dherani, M, Diaz-Torne, C, Dolk, H, Dorsey, ER, Driscoll, T, Duber, H, Ebel, B, Edmond, K, Elbaz, A, Ali, SE, Erskine, H, Erwin, PJ, Espindola, P, Ewoigbokhan, SE, Farzadfar, F, Feigin, V, Felson, DT, Ferrari, A, Ferri, CP, Fevre, EM, Finucane, MM, Flaxman, S, Flood, L, Foreman, K, Forouzanfar, MH, Fowkes, FGR, Franklin, R, Fransen, M, Freeman, MK, Gabbe, BJ, Gabriel, SE, Gakidou, E, Ganatra, HA, Garcia, B, Gaspari, F, Gillum, RF, Gmel, G, Gosselin, R, Grainger, R, Groeger, J, Guillemin, F, Gunnell, D, Gupta, R, Haagsma, J, Hagan, H, Halasa, YA, Hall, W, Haring, D, Maria Haro, J, Harrison, JE, Havmoeller, R, Hay, RJ, Higashi, H, Hill, C, Hoen, B, Hoffman, H, Hotez, PJ, Hoy, D, Huang, JJ, Ibeanusi, SE, Jacobsen, KH, James, SL, Jarvis, D, Jasrasaria, R, Jayaraman, S, Johns, N, Jonas, JB, Karthikeyan, G, Kassebaum, N, Kawakami, N, Keren, A, Khoo, J-P, King, CH, Knowlton, LM, Kobusingye, O, Koranteng, A, Krishnamurthi, R, Lalloo, R, Laslett, LL, Lathlean, T, Leasher, JL, Lee, YY, Leigh, J, Lim, SS, Limb, E, Lin, JK, Lipnick, M, Lipshultz, SE, Liu, W, Loane, M, Ohno, SL, Lyons, R, Ma, J, Mabweijano, J, MacIntyre, MF, Malekzadeh, R, Mallinger, L, Manivannan, S, Marcenes, W, March, L, Margolis, DJ, Marks, GB, Marks, R, Matsumori, A, Matzopoulos, R, Mayosi, BM, McAnulty, JH, McDermott, MM, McGill, N, McGrath, J, Elena Medina-Mora, M, Meltzer, M, Mensah, GA, Merriman, TR, Meyer, A-C, Miglioli, V, Miller, M, Miller, TR, Mitchell, PB, Mocumbi, AO, Moffitt, TE, Mokdad, AA, Monasta, L, Montico, M, Moradi-Lakeh, M, Moran, A, Morawska, L, Mori, R, Murdoch, ME, Mwaniki, MK, Naidoo, K, Nair, MN, Naldi, L, Narayan, KMV, Nelson, PK, Nelson, RG, Nevitt, MC, Newton, CR, Nolte, S, Norman, P, Norman, R, O'Donnell, M, O'Hanlon, S, Olives, C, Omer, SB, Ortblad, K, Osborne, R, Ozgediz, D, Page, A, Pahari, B, Pandian, JD, Rivero, AP, Patten, SB, Pearce, N, Perez Padilla, R, Perez-Ruiz, F, Perico, N, Pesudovs, K, Phillips, D, Phillips, MR, Pierce, K, Pion, S, Polanczyk, GV, Polinder, S, Pope, CA, Popova, S, Porrini, E, Pourmalek, F, Prince, M, Pullan, RL, Ramaiah, KD, Ranganathan, D, Razavi, H, Regan, M, Rehm, JT, Rein, DB, Remuzzi, G, Richardson, K, Rivara, FP, Roberts, T, Robinson, C, De Leon, FR, Ronfani, L, Room, R, Rosenfeld, LC, Rushton, L, Sacco, RL, Saha, S, Sampson, U, Sanchez-Riera, L, Sanman, E, Schwebel, DC, Scott, JG, Segui-Gomez, M, Shahraz, S, Shepard, DS, Shin, H, Shivakoti, R, Singh, D, Singh, GM, Singh, JA, Singleton, J, Sleet, DA, Sliwa, K, Smith, E, Smith, JL, Stapelberg, NJC, Steer, A, Steiner, T, Stolk, WA, Stovner, LJ, Sudfeld, C, Syed, S, Tamburlini, G, Tavakkoli, M, Taylor, HR, Taylor, JA, Taylor, WJ, Thomas, B, Thomson, WM, Thurston, GD, Tleyjeh, IM, Tonelli, M, Towbin, JRA, Truelsen, T, Tsilimbaris, MK, Ubeda, C, Undurraga, EA, van der Werf, MJ, van Os, J, Vavilala, MS, Venketasubramanian, N, Wang, M, Wang, W, Watt, K, Weatherall, DJ, Weinstock, MA, Weintraub, R, Weisskopf, MG, Weissman, MM, White, RA, Whiteford, H, Wiersma, ST, Wilkinson, JD, Williams, HC, Williams, SRM, Witt, E, Wolfe, F, Woolf, AD, Wulf, S, Yeh, P-H, Zaidi, AKM, Zheng, Z-J, Zonies, D, Lopez, AD, and Murray, CJL

Abstract

BACKGROUND: Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and monitoring of individual and population health. The Global Burden of Disease (GBD) studies done in 1990 and 2000 have been the only studies to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level. Neither effort quantified uncertainty in prevalence or years lived with disability (YLDs). METHODS: Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis of prevalence, incidence, remission, duration, and excess mortality. Sources included published studies, case notification, population-based cancer registries, other disease registries, antenatal clinic serosurveillance, hospital discharge data, ambulatory care data, household surveys, other surveys, and cohort studies. For most sequelae, we used a Bayesian meta-regression method, DisMod-MR, designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, we used natural history models, geospatial models, back-calculation models (models calculating incidence from population mortality rates and case fatality), or registration completeness models (models adjusting for incomplete registration with health-system access and other covariates). Disability weights for 220 unique health states were used to capture the severity of health loss. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods. We included uncertainty estimates at all stages of the analysis. FINDINGS: Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged from fewer than one case per 1 million people to 350,000 cases per 1 million people. Prevalence and severity of health loss were weakly cor

Published
2012

29. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

Author

Ruggenenti, P, Lauria, G, Iliev, I, Fassi, A, Ilieva, A, Rota, S, Chiurchiu, C, Barlovic, D, Sghirlanzoni, A, Lombardi, R, Penza, P, Cavaletti, G, Piatti, M, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, A, Trevisan, R, Remuzzi, G, DEMAND Study, I, Parvanova, I, Petrov, I, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Marzorati, L, Marmiroli, P, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, G, Ganeva, M, Cannata, A, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, Gardini, F, Iliev, IP, Ilieva, AP, Barlovic, DP, CAVALETTI, GUIDO ANGELO, Piatti, ML, Dodesini, AR, TREVISAN, ROBERTO, DEMAND Study Investigators, Parvanova, IA, Petrov, II, MARMIROLI, PAOLA LORENA, Giuliano, GA, Cannata, AN, Lauria, G., Ruggenenti, P, Lauria, G, Iliev, I, Fassi, A, Ilieva, A, Rota, S, Chiurchiu, C, Barlovic, D, Sghirlanzoni, A, Lombardi, R, Penza, P, Cavaletti, G, Piatti, M, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, A, Trevisan, R, Remuzzi, G, DEMAND Study, I, Parvanova, I, Petrov, I, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Marzorati, L, Marmiroli, P, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, G, Ganeva, M, Cannata, A, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, Gardini, F, Iliev, IP, Ilieva, AP, Barlovic, DP, CAVALETTI, GUIDO ANGELO, Piatti, ML, Dodesini, AR, TREVISAN, ROBERTO, DEMAND Study Investigators, Parvanova, IA, Petrov, II, MARMIROLI, PAOLA LORENA, Giuliano, GA, Cannata, AN, and Lauria, G.

Abstract

To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria <200 mg/min included in a multicenter, double-blind, placebo-controlled trial (DEMAND [Delapril and Manidipine for Nephroprotection in Diabetes]) and randomized to 3-year treatment with manidipine/delapril combination (10/30 mg/d; n=126), delapril (30 mg/d; n=127), or placebo (n=127). GFR was centrally measured by iohexol plasma clearance. Median monthly GFR decline (interquartile range [IQR]) was 0.32 mL/min per 1.73 m(2) (IQR: 0.16-0.50 mL/min per 1.73 m(2)) on combined therapy, 0.36 mL/min per 1.73 m(2) (IQR: 0.18-0.53 mL/min per 1.73 m(2)) on delapril, and 0.30 mL/min per 1.73 m(2) (IQR: 0.12-0.50 mL/min per 1.73 m(2)) on placebo (P=0.87 and P=0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04-0.78; P=0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07-0.99; P=0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24-0.87; P=0.017) and 0.52 (0.27-0.99; P=0.048), respectively. Glucose disposal rate decreased from 5.8±2.4 to 5.3±1.9 mg/kg per min on placebo (P=0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline bu

Published
2011

31. Status and noise limit of the VIRGO antenna

Author

Babusci, D, Fang, H, Giordano, G, Iannarelli, M, Matone, G, Turri, E, Mazzoni, M, Stanga, R, Calloni, E, Cavaliere, S, Fiore, Di, Evangelista, L, Garifi, G, Grado, F, Milano, A, Solimeno, L, Cagnoli, S, Cattuto, G, Kovalik, C, Marchesoni, J, Punturo, F, Bernardini, M, Bozzi, M, Braccini, A, Bradaschia, S, Casciano, C, Cella, C, Ciampa, G, Cuoco, A, Curci, E, D'Ambrosio, G, Dattilo, E, V, Carolis, De, G, Salvo, De, R, Virgilio, Di, Enard, A, Errico, D, Feng, A, Ferrante, Isidoro, Fidecaro, Francesco, Frasconi, F, Gaddi, F, Gennai, A, Gennaro, A, Giazotto, G, A, Penna, La, Losurdo, P, Maggiore, G, Mancini, M, Palla, S, Pan, F, Paoletti, Hb, Pasqualetti, F, Passaquieti, Roberto, Passuello, R, D, Poggiani, Rosa, Popolizio, P, Raffaelli, F, Rapisarda, S, Taddei, R, Vicere, A, Zhang, Z, Astone, P, Bronzini, F, Frasca, S, Majorana, E, Palomba, C, Perciballi, M, Puppo, P, Rapagnani, P, Ricci, F, Boccara, C, Daban, Jb, Leliboux, M, Loriette, V, Nahoum, R, Roger, Jp, Ganau, P, Lagrange, B, Mackowski, Jm, Michel, C, Morgago, N, Pinard, L, Remillieux, A, Arnault, C, Barrand, C, Beney, Jl, Bilhaut, R, Brisson, V, Cavalier, F, Chiche, R, Coulon, Jp, Cuzon, S, Davier, M, Dehamme, M, Dialinas, M, Eder, C, Gaspard, M, Hello, P, Heusse, P, Hrisoho, A, Jules, E, Marrucho, Jc, Mencik, M, Marin, P, Matone, L, Reboux, A, Roudier, P, Taurigna, M, Bellachia, F, Bermond, M, Boget, D, Caron, B, Carron, T, Castellazzi, D, Chollet, F, Daguin, G, David, Py, Derome, L, Drezen, C, Dufournaud, D, Flamino, R, Giacobone, L, Girard, C, Grave, X, Hermel, R, Lacotte, Jc, Marec, Le, Lieunard, Jc, Marion, B, Massonnet, F, Mehmel, L, Morand, C, Mours, R, Mugnier, B, Sannibale, P, Sottile, V, Verkindt, R, Yvert, D, Acker, M, Barillet, Y, Barsuglia, R, Berthet, M, Brillet, Jp, Cachenaut, A, Cleva, J, Heitmann, F, Innocent, H, Lucenay, Jm, Man, Jc, Manh, Nc, Marck, Pt, Pelat, Ja, Reita, D, and Vinet, V

Subjects
Physics, Optics, business.industry, Limit (mathematics), Antenna (radio), business, Noise (radio)
Published
1998

32. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis

Author

Laura Clarke, Simon Arnett, Wajih Bukhari, Elham Khalilidehkordi, Sofia Jimenez Sanchez, Cullen O'Gorman, Jing Sun, Kerri M. Prain, Mark Woodhall, Roger Silvestrini, Christine S. Bundell, David A. Abernethy, Sandeep Bhuta, Stefan Blum, Mike Boggild, Karyn Boundy, Bruce J. Brew, Wallace Brownlee, Helmut Butzkueven, William M. Carroll, Cella Chen, Alan Coulthard, Russell C. Dale, Chandi Das, Marzena J. Fabis-Pedrini, David Gillis, Simon Hawke, Robert Heard, Andrew P. D. Henderson, Saman Heshmat, Suzanne Hodgkinson, Trevor J. Kilpatrick, John King, Christopher Kneebone, Andrew J. Kornberg, Jeannette Lechner-Scott, Ming-Wei Lin, Christopher Lynch, Richard A. L. Macdonell, Deborah F. Mason, Pamela A. McCombe, Jennifer Pereira, John D. Pollard, Sudarshini Ramanathan, Stephen W. Reddel, Cameron P. Shaw, Judith M. Spies, James Stankovich, Ian Sutton, Steve Vucic, Michael Walsh, Richard C. Wong, Eppie M. Yiu, Michael H. Barnett, Allan G. K. Kermode, Mark P. Marriott, John D. E. Parratt, Mark Slee, Bruce V. Taylor, Ernest Willoughby, Fabienne Brilot, Angela Vincent, Patrick Waters, and Simon A. Broadley

Subjects
neuromyelitis optica, multiple sclerosis, magnetic resonance imaging, diagnosis, NMOSD, Neurology. Diseases of the nervous system, RC346-429
Abstract

Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the CNS. Overlap in the clinical and MRI features of NMOSD and MS means that distinguishing these conditions can be difficult. With the aim of evaluating the diagnostic utility of MRI features in distinguishing NMOSD from MS, we have conducted a cross-sectional analysis of imaging data and developed predictive models to distinguish the two conditions. NMOSD and MS MRI lesions were identified and defined through a literature search. Aquaporin-4 (AQP4) antibody positive NMOSD cases and age- and sex-matched MS cases were collected. MRI of orbits, brain and spine were reported by at least two blinded reviewers. MRI brain or spine was available for 166/168 (99%) of cases. Longitudinally extensive (OR = 203), “bright spotty” (OR = 93.8), whole (axial; OR = 57.8) or gadolinium (Gd) enhancing (OR = 28.6) spinal cord lesions, bilateral (OR = 31.3) or Gd-enhancing (OR = 15.4) optic nerve lesions, and nucleus tractus solitarius (OR = 19.2), periaqueductal (OR = 16.8) or hypothalamic (OR = 7.2) brain lesions were associated with NMOSD. Ovoid (OR = 0.029), Dawson's fingers (OR = 0.031), pyramidal corpus callosum (OR = 0.058), periventricular (OR = 0.136), temporal lobe (OR = 0.137) and T1 black holes (OR = 0.154) brain lesions were associated with MS. A score-based algorithm and a decision tree determined by machine learning accurately predicted more than 85% of both diagnoses using first available imaging alone. We have confirmed NMOSD and MS specific MRI features and combined these in predictive models that can accurately identify more than 85% of cases as either AQP4 seropositive NMOSD or MS.

Published
2021
Full Text
View/download PDF

36. Glomerular hyperfiltration and renal disease progression in type 2 diabetes.

Author

Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G, GFR Study Investigators, Ruggenenti, Piero, Porrini, Esteban L, and Gaspari, Flavio

Abstract

Objective: To describe the prevalence and determinants of hyperfiltration (glomerular filtration rate [GFR] ≥120 mL/min/1.73 m(2)), GFR decline, and nephropathy onset or progression in type 2 diabetic patients with normo- or microalbuminuria.Research Design and Methods: We longitudinally studied 600 hypertensive type 2 diabetic patients with albuminuria <200 μg/min and who were retrieved from two randomized trials testing the renal effect of trandolapril and delapril. Target blood pressure (BP) was <120/80 mmHg, and HbA(1c) was <7%. GFR, albuminuria, and glucose disposal rate (GDR) were centrally measured by iohexol plasma clearance, nephelometry in three consecutive overnight urine collections, and hyperinsulinemic euglycemic clamp, respectively.Results: Over a median (range) follow-up of 4.0 (1.7-8.1) years, GFR declined by 3.37 (5.71-1.31) mL/min/1.73 m(2) per year. GFR change was bimodal over time: a larger reduction at 6 months significantly predicted slower subsequent decline (coefficient: -0.0054; SE: 0.0009), particularly among hyperfiltering patients. A total of 90 subjects (15%) were hyperfiltering at inclusion, and 11 of 47 (23.4%) patients with persistent hyperfiltration progressed to micro- or macroalbuminuria versus 53 (10.6%) of the 502 who had their hyperfiltration ameliorated at 6 months or were nonhyperfiltering since inclusion (hazard ratio 2.16 [95% CI 1.13-4.14]). Amelioration of hyperfiltration was independent of baseline characteristics or ACE inhibition. It was significantly associated with improved BP and metabolic control, amelioration of GDR, and slower long-term GFR decline on follow-up.Conclusions: Despite intensified treatment, patients with type 2 diabetes have a fast GFR decline. Hyperfiltration affects a subgroup of patients and may contribute to renal function loss and nephropathy onset or progression. Whether amelioration of hyperfiltration is renoprotective is worth investigating. [ABSTRACT FROM AUTHOR]

Published
2012

37. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.

Author

Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, and Nalysnyk L

Abstract

OBJECTIVE: To examine the relationship between international normalized ratio (INR) and outcomes (major bleeding events and strokes) in patients with atrial fibrillation (AF) receiving anticoagulation with warfarin. METHODS: A systematic review and metaanalysis of studies published in the English language between January 1, 1985, and October 30, 2002, was performed. MEDLINE (PubMed), Current Contents, and relevant reference lists were searched. Studies enrolling patients with nonvalvular AF receiving warfarin anticoagulation were eligible for inclusion if they reported stroke and/or major bleeding events in relation to INR, or time spent in therapeutic range. The risk of bleeds in overanticoagulated patients (INR > 3) and the risk of strokes in underanticoagulated patients (INR < 2) were assessed. RESULTS: Twenty-one studies (6,248 patients) met all inclusion criteria. Of the 21 studies, a target conventional INR of 2 to 3 was used in 9 studies. An INR < 2, compared with an INR > or = 2, was associated with an odds ratio (OR) for ischemic events of 5.07 (95% confidence interval [CI], 2.92 to 8.80). An INR > 3, compared with an INR < or = 3, was associated with an OR for bleeding events of 3.21 (95% CI, 1.24 to 8.28). On average, in the four studies with a target INR range of 2 to 3, patients with AF receiving warfarin spent 61% of time within, 13% of time above, and 26% below the therapeutic range. CONCLUSION: Available evidence indicates that in patients with nonvalvular AF, the risk of ischemic stroke with insufficient warfarin anticoagulation (INR < 2), and the risk of bleeding events with overanticoagulation (INR > 3) are significantly higher relative to patients with AF maintained within the recommended INR of 2 to 3. However, the published data are sparse, heterogeneous, and primarily reported from clinical trials. More studies evaluating clinical outcomes in relation to INR are needed, especially in a real-world setting. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

38. State Medicaid Coverage for Tobacco-Dependence Treatments--United States, 2006.

Author

Halpin, H. A., McMenamin, S. B., Cella, C. A., Bellows, N. M., and Husten, C. G.

Subjects
CIGARETTE smokers, MEDICAID, NICOTINE addiction treatment, TREATMENT of drug addiction, HEALTH insurance, HUMAN services
Abstract

The article presents a discussion of the types of tobacco-dependence treatments that are covered by Medicaid programs. It is noted that one in 3 adults who receive Medicaid in the U.S. smoke tobacco. The results of a survey conducted by the Center for Health and Public Policy Studies at the University of California, Berkeley in 2006 is summarized. Results showed 39 state Medicaid programs provided coverage for some form of tobacco-dependence treatment. Some Medicaid programs had limitations for these treatments including prior authorization, co-payments and duration of coverage.

Published
2008
Full Text
View/download PDF

39. State Medicaid Coverage for Tobacco-Dependence Treatments--United States, 2005.

Author

Halpin, H. A., McMenamin, S. B., Cella, C. A., Husten, C. C., and Rosenthal, Abby

Subjects
MEDICAID, NICOTINE addiction treatment, MEDICAID beneficiaries, HEALTH insurance, MEDICAL care of poor people, HEALTH policy, SUBSTANCE abuse treatment
Abstract

The article summarizes and explores the results of a 2005 survey conducted among all states in the U.S. regarding the types of Medicaid coverage provided for the treatment of tobacco dependence since 1994. Findings included that 38 state programs provided coverage for some form of treatment for all recipients, four provided coverage only to women who were pregnant, and Oregon provided full coverage for all recommended treatments articulated in the 2000 Public Health Service guideline. Methods used to conduct the survey and possible limitations to report findings are presented.

Published
2006
Full Text
View/download PDF

40. Diagnosis and First-Line Treatment of Patients with Lung Cancer in Italian General Hospitals

Author

Alexanian, Alexan, Apolone, Giovanni, Roberto Grilli, Roldano Fossati, Mosconi, Paola, Nicolucci, Antonio, Liberati, Alessandro, Di Biagio, G., Testore, F., Michetti, G., Beltrami, V., Iarussi, T., Bonati, P.L., Rossetti, A., Buccheri, G.F., Manichetti, C., Indelli, M., Malacarne, P., Ghiringhelli, P., Olivadoti, O., Cella, C., Lepore, S., Isa, L., Scapaticci, R., Sargenti, A., Sevieri, G.F., Lanzetti, V., Nascimben, O., Soresi, E., Mezzetti, M., Confalonieri, C., Pavia, G.F., Rizzi, A., Di Costanzo, F., Tagliaventi, M., Trotti, A. Boidi, Fracchia, F., Rovea, P., Verna, V., and Bian, A. Rosa

Abstract

The quality of diagnostic and therapeutic care was examined in a series of 380 consecutive newly diagnosed cases of primary lung cancer seen in 20 Italian general hospitals between January and June 1987. At diagnosis most patients (78%) had one or more symptoms related to the tumor, and in an additional 9 % symptoms were related to the presence of distant metastases. The median diagnostic time lag between first symptoms and final diagnosis was 50 days with a significantly longer delay in patients first seen by their general practitioner compared with those who sought first care in hospital outpatient departments. The diagnostic process was satisfactorily carried out in fewer than two-thirds of the patients leading to complete ascertainment of disease stage and histology in 58% cases with significantly better performance in more specialized institutions. Analysis of the first-line treatment profile indicated a rather aggressive therapeutic attitude In the case of patients with non-small cell lung cancer – 28% of them had chemotherapy despite the lack of any proof of efficacy in controlled clinical trials – and a failure to identify among the patients with small cell disease those amenable to more aggressive treatment. The lack of progress in the treatment of lung cancer over the last decades seems to have resulted in widely varying practice patterns where a mixture of aggressive and laissez-faire attitudes does not take into account that in the absence of effective therapies a more conservative attitude would at least have some advantage in terms of quality of remaining life for many patients.

Published
1989
Full Text
View/download PDF

43. Effect of native lactobacillus murinus LbP2 administration on total fecal IgA in healthy dogs

Author

Luis Delucchi, Fraga, M., Perelmuter, K., Cella, C. D., and Zunino, P.

Subjects
Immunomodulation, Male, Feces, Lactobacillus, Dogs, Probiotics, Short Communications, Animals, Female, Statistics, Nonparametric, Immunoglobulin A
Abstract

The objective of the present work was to determine the effect of Lactobacillus murinus strain LbP2 on canine fecal immunoglobulin A (IgA) levels. Seven dogs were orally treated with a 3-mL suspension of L. murinus LbP2 containing 5 × 10(9) colony-forming units on alternate days for 2 wk. Six dogs were treated with 3 mL of phosphate-buffered saline as placebo. Fecal samples were taken from the rectal ampulla on days 0 and 16, and the total canine fecal IgA concentration was determined with an immunoperoxidase assay kit. The IgA levels of individual dogs were compared with the nonparametric Wilcoxon test. Differences were considered significant when the P-value was less than 0.05. An increase in the total fecal IgA concentration was observed in the 7 dogs after treatment with L. murinus LbP2 (P = 0.01796). No differences were detected between the initial total fecal IgA values and those obtained at the end of placebo treatment. Thus, after oral administration L. murinus LbP2 showed potential immunomodulatory effects, an important property to assess in a microorganism being considered for use as a probiotic.L’objectif de la présente étude était de déterminer l’effet de la souche

50. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients with Cancer

Author

Chiara A. Cella, Maren Knoedler, Marcia Hall, Michele Arcopinto, Vincenzo Bagnardi, Lorenzo Gervaso, Stefania Pellicori, Francesca Spada, Maria G. Zampino, Paola S. Ravenda, Samuele Frassoni, Antonio Passaro, Monica Milano, Alice Laffi, Nicola Fazio, Florian Lordick, Cella, C, Knoedler, M, Hall, M, Arcopinto, M, Bagnardi, V, Gervaso, L, Pellicori, S, Spada, F, Zampino, M, Ravenda, P, Frassoni, S, Passaro, A, Milano, M, Laffi, A, Fazio, N, and Lordick, F

Subjects
Risk Prediction Model, General Medicine, Venous Thromboembolism
Abstract

ImportanceThe assessment of the risk of venous thromboembolism (VTE) among outpatients with cancer represents an unsolved topic. Current international guidelines recommend primary prophylaxis for patients at intermediate to high risk of VTE, indicated by a Khorana score of 2 or more. A previous prospective study developed the ONKOTEV score, a 4-variable risk assessment model (RAM) consisting of a Khorana score of more than 2, metastatic disease, vascular or lymphatic compression, and previous VTE event.ObjectiveTo validate the ONKOTEV score as a novel RAM to assess the risk of VTE among outpatients with cancer.Design, Setting, and ParticipantsONKOTEV-2 is a noninterventional prognostic study conducted in 3 European centers located in Italy, Germany, and the United Kingdom among a prospective cohort of 425 ambulatory patients with a histologically confirmed diagnosis of a solid tumor who were receiving active treatments. The total study duration was 52 months, with an accrual period of 28 months (from May 1, 2015, to September 30, 2017) and an overall follow up-period of 24 months (data were censored September 30, 2019). Statistical analysis was performed in October 2019.ExposuresThe ONKOTEV score was calculated for each patient at baseline by collecting clinical, laboratory, and imaging data from tests performed for routine practice. Each patient was then observed to detect any thromboembolic event throughout the study period.Main Outcomes and MeasuresThe primary outcome of the study was the incidence of VTE, including deep vein thrombosis and pulmonary embolism.ResultsA total of 425 patients (242 women [56.9%]; median age, 61 years [range, 20-92 years]) were included in the validation cohort of the study. The cumulative incidences for the risk of developing VTE at 6 months were 2.6% (95% CI, 0.7%-6.9%), 9.1% (95% CI, 5.8%-13.2%), 32.3% (95% CI, 21.0%-44.1%), and 19.3% (95% CI, 2.5%-48.0%), respectively, among 425 patients with an ONKOTEV score of 0, 1, 2, and greater than 2 (P Conclusions and RelevanceThis study suggests that, because the ONKOTEV score has been validated in this independent study population as a novel predictive RAM for cancer-associated thrombosis, it can be adopted into practice and into clinical interventional trials as a decision-making tool for primary prophylaxis.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results